Elicio Therapeutics Inc
NASDAQ:ELTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ELTX's latest stock split occurred on Jun 2, 2023
The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.
Before the split, ELTX traded at 1 per share. Afterward, the share price was about 18.145.
The adjusted shares began trading on Jun 2, 2023. This was the only stock split in ELTX's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 21, 2026
|
W
|
WellCell Holdings Co Ltd
HKEX:2477
|
4-for-1
x4
|
111.28 111.28 HKD | N/A |
|
Apr 21, 2026
|
|
Canon Electronics Inc
TSE:7739
|
1-for-6235122
/6235122
|
3635 3635 JPY | N/A |
|
Apr 20, 2026
|
|
AnaptysBio Inc
NASDAQ:ANAB
|
15-for-10
x1.5
|
67.5101 45.0067 USD | 50.95 50.95 USD |
|
Apr 20, 2026
|
|
ConnectM Technology Solutions Inc
NASDAQ:CNTM
|
1-for-32
/32
|
0.265 8.48 USD | 8.48 8.48 USD |
|
Apr 20, 2026
|
M
|
Mdundocom A/S
CSE:MDUNDO
|
10-for-9
x1.1111111111111
|
1.25 1.125 DKK | 1.03 1.03 DKK |
7739
ANAB
CNTM
Elicio Therapeutics Inc
Glance View
Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. The company is headquartered in Boston, Massachusetts and currently employs 3 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. The company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The firm's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). The company is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The firm is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The firm provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The firm conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
